Eli Lilly and Company (LLY) is a global leader in healthcare innovation, specializing in discovering, developing, and ...
Eli Lilly (LLY) reduced its fourth-quarter sales guidance by 5%, lowering expectations to $13.5 billion. This figure is $400 ...
Eli Lilly and Co (NYSE: LLY) announced that it expects 2024 full-year worldwide revenue to be approximately $45.0 billion, ...
Eli Lilly and Company LLY dropped 6.6% in the Jan. 14 trading session after slashing its revenue guidance for the fourth ...
Turning to 2025 guidance, Lilly noted that new medicines and new uses of existing medicines, expansion of production, and ...
When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...
Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.
David A. Ricks, Lilly’s CEO, attributed some of the shortfall to supply chain dynamics, noting that despite the setbacks, manufacturing capacity for incretin products is set to increase by at least 60 ...
The London Metal Exchange is in its final stages to approve Hong Kong as the main warehousing network for its metals.
Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...
The Indianapolis, Indiana-based company is set to release its Q4 earnings on Tuesday, Feb. 4. Ahead of the event, analysts expect Eli Lilly to report a profit of $5.43 per share, up 118.1% from ...